|
 | Up a level |
Gentilini, Arianna (2025) Expanding access to NCD services via community retail pharmacies in LMICs: a systematic literature review. Journal of Pharmaceutical Policy and Practice. ISSN 2052-3211 (In Press)
Gentilini, Arianna and Rana, Alina (2024) How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals. European Journal of Health Economics. ISSN 1618-7598
Gentilini, Arianna, Neez, Emilie and Wong-Rieger, Durhane (2024) Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions. Value in Health. ISSN 1098-3015 (In Press)
Gentilini, Arianna and Parvanonva, Iva (2024) Managing experts’ conflicts of interest in the EU joint clinical assessment. BMJ Open, 14 (11). e091777. ISSN 2044-6055
Jenei, Kristina, Gentilini, Arianna, Haslam, Alyson and Prasad, Vinay (2024) Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. The Lancet Oncology, 25 (8). 979 - 988. ISSN 1470-2045
Gentilini, Arianna and Miraldo, Marisa (2023) The role of patient organizations on research and development: evidence from rare diseases. Social Science & Medicine, 338. ISSN 0277-9536
Gentilini, Arianna and Parvanova, Iva (2023) Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence. BMJ Open, 13 (6). ISSN 2044-6055
Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan and Naci, Huseyin 
ORCID: 0000-0002-7192-5751
(2023)
Safeguarding NICE from patient groups' conflicts of interest.
BMJ, 381.
ISSN 0959-8146
Kamphuis, Bregtje, Fontrier, Anna-Maria, Haig, Madeleine, Politopoulou, Konstantina, Salyga, Hana, Gentilini, Arianna and Kanavos, Panos ORCID: 0000-0001-9518-3089
(2021)
Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia.
.
LSE Consulting, London, UK.
